[criticaltinker]

I know you comment on a wide range of topics here, and perhaps you’re jaded by some personal experiences with local ketamine clinics - but IMO your tone comes across as unnecessarily pessimistic and a smidge anecdotal.

Ketamine/MDMA/LSD/Psilocybin and their derivatives are on their way to being recognized as the safest, most effective, and widely available medicines - for nearly every common mental health disorder - currently known to humanity.

Yes there will always be predatory behavior in healthcare, and regulation can help. And of course no medicine is 100% side-effect free or effective for everyone.

But shouldn’t we be complaining that many of these substances continue to remain federally outlawed in the US despite a huge body of scientific evidence and multiple companies discussing phase 3 clinical trials with the FDA this year?

I don’t really hear many folks calling for tighter regulation on these substances, especially given the current regulatory situation.

[PragmaticPulp]

> Ketamine/MDMA/LSD/Psilocybin and their derivatives are on their way to being recognized as the safest, most effective, and widely available medicines - for nearly every common mental health disorder - currently known to humanity.

This sounds like a utopian fantasy.

Ketamine can be useful, but like I said it’s not a long-term solution.

MDMA isn’t really safe for extended use. Even the MDMA enthusiasts will agree with that one.

Psilocybin is being studied in conjunction with 10-20 therapy sessions. If you’re attributing the positive effects from studies to the drug alone, that’s incorrect. Someone taking MDMA or mushrooms on their own is nothing like what’s being studied.

I’m optimistic about future research, but if you think Ketamine, MDMA, and Psilocybin are the safest and most effective drugs available for “nearly all” mental health issues then you’re not really discussing the research, you’re discussing a utopian fantasy. Even the researchers I know in this space aren’t anywhere near that idealistic. Let’s be realistic.

[criticaltinker]

I'm afraid you're misrepresenting this important area of research.

> Psilocybin is being studied in conjunction with 10-20 therapy sessions

For a quick reality check, you could take a look at Compass Pathways and their phase 1 & 2 clinical trial results [1][2]:

> we have completed a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This was the largest randomised, controlled, double-blind psilocybin therapy clinical trial ever conducted, and our topline data showed a statistically significant (p<0.001) and clinically relevant improvement for patients who received a single high dose of COMP360 psilocybin with psychological support

That is a single dose along with a single therapy session, showing positive benefits lasting 12+ weeks. For treatment resistant depression (TRD), a notoriously difficult condition to cure and one that affects many people.

There are literally no other drugs on the market that come close to the safety, efficacy, and durability profile that is being observed!

Do you think the FDA granted breakthrough therapy status in 2018 because of some collective "utopian fantasy"?

It's well known there are numerous indications for psychedelic assisted therapy showing great promise - from anxiety and addiction to end of life care [3]. It's not just psilocybin either, many of these psychedelic substances are pharmacologically related - so they act on similar receptors and areas of the brain, and thus have similar therapeutic profiles [4].

Let's be realistic. Your appeal to extremes is an uncharitable interpretation of my comment, and frankly your uninformed pessimism on this topic is a disservice to anyone interested in learning about or benefiting from these advances.

[1] https://ir.compasspathways.com/news-releases/news-release-de...

[2] https://ir.compasspathways.com/static-files/0f9fbce8-2619-43...

[3] https://www.sciencedirect.com/science/article/pii/S009286742...

[4] https://www.nature.com/articles/s41386-022-01297-2

[mrcartmeneses]

> ...like I said it’s not a long-term solution.

The above statement does not correlate with current research